The economics of temozolomide in brain cancer

• BLEEHEN NM, STENNING SP: A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br. J. Cancer (1991) 64(4):769-774.
   PubMed Web of Science ®Google Scholar
• BRADA M, HOANG-XUAN K, RAMPLING R et al.: Multicenter Phase II trial of temozolomide in patients with glioblastomamultiforme at first relapse. Ann. Oncol. (2001) 12(2):259-266.
   PubMed Web of Science ®Google Scholar
• VAN DEN BENT MJ, TAPHOORN MJ, BRANDES AA et al.: European Organization for Research and Treatment of Cancer Brain Tumor Group. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol. (2003) 21(13):2525-2528.
   PubMed Web of Science ®Google Scholar
• STEWART LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet (2002) 359(9311):1011-1018.
   PubMed Web of Science ®Google Scholar
• STUPP R, MASON WP, VAN DEN BENT MJ et al.: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996.
   PubMed Web of Science ®Google Scholar
• ATHANASSIOU H, SYNODINOU M, MARAGOUDAKIS E et al.: Randomized Phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J. Clin. Oncol. (2005) 23(10):2372-2377.
   Google Scholar
• TAPHOORN MJ, STUPP R, COENS C et al.: European Organisation for Research and Treatment of Cancer Brain Tumour Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. (2005) 6(12):937-944.
   PubMed Web of Science ®Google Scholar
• OSOBA D, BRADA M, YUNG WK, PRADOS M: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. (2000) 18(7):1481-1491.
   PubMed Web of Science ®Google Scholar
• OSOBA D, BRADA M, YUNG WK, PRADOS MD: Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur. J. Cancer (2000) 36(14):1788-1795.
   PubMed Web of Science ®Google Scholar
• WASSERFALLEN JB, OSTERMANN S, PICA A et al.: Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer (2004) 101(9):2098-2105.
   PubMed Web of Science ®Google Scholar
• WASSERFALLEN JB, OSTERMANN S, LEYVRAZ S, STUPP R: Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol. (2005) 7(2):189-195.
   PubMed Web of Science ®Google Scholar
• STUPP R, DIETRICH PY, OSTERMANN KS et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. (2002) 20(5):1375-1382.
   PubMed Web of Science ®Google Scholar
• GREANYA ED, TAYLOR SCM, HU F, BARNETT J, THIESSEN B: Temozolomide for malignant gliomas in British Columbia: A population-based cost-effectiveness analysis. J. Oncol. Pharm. Prac. (2004) 10:201-209.
   Google Scholar
• MARTIKAINEN JA, KIVIOJA A, HALLINEN T, VIHINEN P: Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. Pharmacoeconomics (2005) 23(8):803-815.
   PubMed Web of Science ®Google Scholar
• DINNES J, CAVE C, HUANG S, MAJOR K, MILNE R: The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. Health Technol. Assess. (2001) 5(13):1-73.
   PubMedGoogle Scholar
• DINNES J, CAVE C, HUANG S, MILNE R: A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer (2002) 86(4):501-505.
   PubMed Web of Science ®Google Scholar
• UYL-DE GROOT CA, LEIDA ML, MAIWENN J et al.: Cost-effectiveness of temozolomide for the treatment of newly diagnosed gliobastoma multiforme in the UK. ISPOR 8th European Congress, Florence (6 – 8 November 2005) (Abstract).
   Google Scholar
• FRIEDMAN HS, KERBY T, CALVERT H: Temozolomide and treatment of malignant glioma. Clin. Cancer. Res. (2000) 6(7):2585-2597.
   PubMed Web of Science ®Google Scholar
• HEGI ME, DISERENS AC, GORLIA T et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. (2005) 352(10):997-1003.
   PubMed Web of Science ®Google Scholar
• STUPP R, VAN DEN BENT MJ, HEGI ME: Optimal role of temozolomide in the treatment of malignant gliomas. Curr. Neurol. Neurosci. Rep. (2005) 5(3):198-206.
   PubMedGoogle Scholar
• STUPP R, HEGI ME, VAN DEN BENT MJ et al.: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Changing paradigms – an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 11(2):165-180.
   PubMed Web of Science ®Google Scholar
• MIRIMANOFF RO, GORLIA T, MASON W et al.: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 Phase III randomized trial. J. Clin. Oncol. (2006) 24(16):2563-2569.
   PubMed Web of Science ®Google Scholar
• REARDON DA, RICH JN, FRIEDMAN HS, BIGNER DD: Recent advances in the treatment of malignant astrocytoma. J. Clin. Oncol. (2006) 24(8):1253-1265.
   PubMed Web of Science ®Google Scholar
• DIMASI JA, PAQUETTE C: The economics of follow-on drug research and development: trends in entry rates and the timing of development. Pharmacoeconomics (2004) 22(Suppl. 2):1-14.
   PubMed Web of Science ®Google Scholar
• DIMASI JA, GRABOWSKI HG: Economics of new oncology drug development. J. Clin. Oncol. (2007) 25(2):209-216.
   PubMed Web of Science ®Google Scholar

Websites

• NICE: http://www.nice.org.uk/page.aspx?o=285589&c=cancer (Accessed on 08 October 2006).
   Google Scholar
• PentaG: http://www.pms.ac.uk/pms/research/pentag.php (Accessed on 08 October 2006).
   Google Scholar